Date |
|
Oct 20, 2014 |
CEL-SCI Corporation Announces Proposed Public Offering of Common Stock and Warrants |
Oct 3, 2014 |
CEL-SCI Enrolls 16 Patients in September in Its Phase III Immunotherapy Head and Neck Cancer Trial |
Sep 29, 2014 |
CEL-SCI & U.S. Navy Administer Multikine to First Volunteer Patient in Phase I Clinical Trial for Treatment of Anal Warts in HIV/HPV Co-Infected Patients |
Sep 10, 2014 |
University of Minnesota Masonic Cancer Center Joins CEL-SCI’s Phase III Head & Neck Cancer Trial |
Sep 3, 2014 |
CEL-SCI Enrolls 20 Patients in August in Its Phase III Immunotherapy Head and Neck Cancer Trial |
Aug 19, 2014 |
CEL-SCI Expands its Global Phase III Immunotherapy Head and Neck Cancer Trial into Centre Hospitalier Universitaire de Quebec in Canada |
Aug 8, 2014 |
CEL-SCI Corporation Reports Third Quarter Fiscal 2014 Financial Results |
Aug 1, 2014 |
CEL-SCI Achieves Milestone in July with Total of 232 Patients Enrolled to Date in Its Phase III Head and Neck Cancer Trial |
Jul 30, 2014 |
France Becomes 17th Country to Clear CEL-SCI for Patient Enrollment in Its Global Phase III Head and Neck Cancer Trial |
Jul 22, 2014 |
CEL-SCI Receives Regulatory Clearance to Expand Phase III Head and Neck Cancer Trial into Turkey |